Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB072A | — |
the lyophilized portion of Menveo (2-vial) presentation was reconstituted with sterile water and administered to a pt.; the lyophilized portion of Menveo (2-vial) presentation was reconstituted with sterile water and administered to a pt.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 12-year-old patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB072A, expiry date 30-APR-2026) for prophylaxis. On 31-JUL-2025, the patient received Menveo. On 31-JUL-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: the lyophilized portion of Menveo (2-vial) presentation was reconstituted with sterile water and administered to a pt.) and inappropriate dose of vaccine administered (Verbatim: the lyophilized portion of Menveo (2-vial) presentation was reconstituted with sterile water and administered to a pt.). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 06-AUG-2025 The reporter reported that the lyophilized portion of Menveo (2-vial) presentation was reconstituted with sterile water and administered to a patient, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered